Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010. Based on clinical data and expert opinion, Herceptin plus chemotherapy has competitive advantages in efficacy relative to other current therapies, and it has shown to significantly improve median overall survival compared with chemotherapy alone.

"Despite the recent approval of Herceptin—the first targeted agent approved for gastric cancer—only HER2-positive patients will be eligible for it. Therefore there is still a very high unmet need for further targeted agents that extend survival of patients," stated Decision Resources Analyst Rachel Webster, Ph.D.

The new report entitled Gastric Cancer (Unresectable): An Emerging Biological Agent Will Take Over as Market Leader in 2013 also finds that a therapy that improves the median overall survival of unresectable gastric cancer patients compared with capecitabine/cisplatin would earn 58 percent patient share in the U.S., according to surveyed U.S. oncologists. In contrast, in Europe, such an agent would earn a lower patient share of 48 percent, according to surveyed European oncologists. The difference in patient share suggests that in Europe, physician prescribing decisions are strongly influenced by reimbursement policies.

"Despite the need for more-efficacious therapies that improve median overall survival and the need for more tolerable therapies that can be used in more patients, reimbursement restrictions in Europe constrain physicians from prescribing novel, premium-priced therapies," added Dr. Webster.

SOURCE Decision Resources

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revolutionary AI tool detects multiple cancers in whole-body PET/CT scans